"EVALUATING ANTIDIABETIC DRUG THERAPIES IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME: BIOCHEMICAL IMPACT AND CARDIOVASCULAR BENEFITS OF SGLT2 INHIBITORS - A CROSS-SECTIONAL STUDY"
Main Article Content
Keywords
Polycystic Ovary Syndrome, Metformin, Vildagliptin, Insulin Resistance, SGLT2 inhibitors
Abstract
Polycystic Ovary Syndrome (PCOS) is a hormonal disorder often associated with insulin resistance. Anti diabetic drugs i.e, SGLT2 inhibitors ,Metformin and Vildagliptin are antidiabetic medications that improve biochemical markers and clinical outcomes in polycystic ovary syndrome patients. Objective: To compare the effectiveness and biochemical impact of anti diabetic drugs i.e Metformin, Vildagliptin,SGLT2 inhibitors in women with PCOS and also explore the cardiovascular benefits of SGLT2 inhibitors. Methodology: This cross-sectional study included women with polycystic ovary syndrome (PCOS) treated with either SGLT2 inhibitors, Metformin and Vildagliptin. Biochemical parameters, including insulin sensitivity, androgen levels, and lipid profiles were measured and assess the cardiovascular protective effects of SGLT2 inhibitors. Results Both Metformin and Vildagliptin improved insulin sensitivity and reduced androgen levels, but Metformin showed greater efficacy in weight reduction and improvement in lipid profiles and SGLT2 inhibitors has cardiovascular protective effects. Conclusion: Antidiabetic drugs are effective in improving biochemical markers in PCOS patients as well as Metformin and SGLT2 inhibitors has additional benefits on heart and lipid profiles may make it a preferred choice for cardiovascular patients.
References
2. Valsamakis, G., Lois, K., Kumar, S. and Mastorakos, G. (2013) Metabolic and Other Effects of Pioglitazone as an Add-On Therapy to Metformin in the Treatment of Polycystic Ovary Syndrome (PCOS). Hormones, 12, 363-378.
3. .Cho, L.W., Kilpatrick, E.S., Keevil, B.G., Coady, A.M. and Atkin, S.L. (2019) Effect of Metformin, Orlistat and Pioglitazone Treatment on Mean Insulin Resistance and Its Biological Variability in Polycystic Ovary Syndrome. Clinical Endocrinology, 70, 233-237.
4. Katsiki, N. and Hatzitolios, A.I. (2020) Insulin-Sensitizing Agents in the Treatment of Polycystic Ovary Syndrome: An Update. Current Opinion in Obstetrics and Gynecology, 22, 466-476.
5. .Ziaee, A., Oveisi, S., Abedini, A., Hashemipour, S., Karimzadeh, T. and Ghorbani, A. (2022) Effect of Metformin and Pioglitazone Treatment on Cardiovascular Risk Profile in Polycystic ovary Syndrome. Acta Medica Indonesiana, 44, 16-22.
6. Lazarus B, Wu A, Shin JI et al. Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based co- hort study. JAMA Intern Med 2018; 178: 903–910
7. Ibanez, L., Lopez-Bermejo, A., Diaz, M., Enriquez, G., Del Rio, L. and De Zegher, F. (2020) Low-Dose Pioglitazone, Flutamide, Metformin plus an Estro-Progestagen for Non-Obese Young Women with Polycystic Ovary Syndrome: Increasing Efficacy and Persistent Safety over 30 Months. Gynecological Endocrinology, 26, 869-873.
8. Jardine MJ, Mahaffey KW, Neal B et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 2017; 46: 462–472
9. .Roe, A., Hillman, J., Butts, S., Smith, M., Rader, D., Playford, M., et al. (2014) Decreased Cholesterol Efflux Capacity and Atherogenic Lipid Profile in Young Women with PCOS. Journal of Clinical Endocrinology & Metabolism, 99, 2013-3918.
10. Du, Q., Wang, Y.J., Yang, S., Wu, B., Han, P. and Zhao, Y.Y. (2012) A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Pioglitazone versus Metformin in the Treatment of Polycystic Ovary Syndrome. Current Medical Research and Opinion, 28, 723-730.
11. .Li, X.J., Yu, Y.X., Liu, C.Q., Zhang, W., Zhang, H.J., Yan, B., et al. (2021) Metformin vs Thiazolidinediones for Treatment of Clinical, Hormonal and Metabolic Characteristics of Polycystic Ovary Syndrome: A Meta-Analysis. Clinical Endocrinology, 74, 332-339.
12. .Haydardedeoglu, B., Simsek, E., Kilicdag, E.B. and Bagis, T. (2019) Metabolic and Endocrine Effects of Metformin and Metformin plus Cyclic Medroxyprogesterone Acetate in Women with Polycystic Ovary Syndrome. International Journal of Gynecology & Obstetrics, 105, 32-35.
13. Ahren, B., Foley, J.E. and Bosi, E. (2019) Clinical Evidence and Mechanistic Basis for Vildagliptin’s Action When Added to Metformin. Diabetes, Obesity and Metabolism, 13, 193-203.
14. Schweizer, A., Couturier, A., Foley, J.E. and Dejager, S. (2017) Comparison between Vildagliptin and Metformin to Sustain Reductions in HbA(1c) over 1 Year in Drug-Naive Patients with Type 2 Diabetes. Diabetic Medicine, 24, 955-961.
15. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657
16. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular out- comes in type 2 diabetes. N EnglJ Med 2019; 380: 347–357
17. .Garber, A.J., Foley, J.E., Banerji, M.A., Ebeling, P., Gudbjornsdottir, S., Camisasca, R.P., et al. (2018) Effects of Vildagliptin on Glucose Control in Patients with Type 2 Diabetes Inadequately Controlled with a Sulphonylurea. Diabetes, Obesity and Metabolism, 10, 1047-1056.
18. .Karagiannis, T., Paschos, P., Paletas, K., Matthews, D.R. and Tsapas, A. (2012) Dipeptidyl Peptidase-4 Inhibitors for Treatment of Type 2 Diabetes Mellitus in the Clinical Setting: Systematic Review and Meta-Analysis. BMJ, 12, e1369.
19. Heerspink HJ, Perkins BA, Fitchett DH et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134: 752–772
20. .Thomson SC, Rieg T, Miracle C et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012; 302: R75–R83
21. .Schweizer, A., Dejager, S., Foley, J.E. and Kothny, W. (2011) Assessing the General Safety and Tolerability of Vildagliptin: Value of Pooled Analyses from a Large Safety Database versus Evaluation of Individual Studies. Vascular Health and Risk Management, 7, 49-57.
22. .Geller, D.H., Pacaud, D., Gordon, C.M. and Misra, M. (2011) State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). International Journal of Pediatric Endocrinology, 26, 1687-9856.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Kashif Khalid
Consultant Medical Specialist & Diabetologist, Altamash General Hospital, Koohi Goth Women’s Hopsital
Muhammad Mujtaba Ali
Professor, Department of Pharmacology, United Medical and Dental College, Karachi
Fareeda Islam
Professor, Dept of Pharmacology, Karachi Medical &Dental College KMC, Karachi
Shabnam Hasan
Associate Professor, Obs and Gynae department, Hamdard University Hospital
Saira Saeed
Associate professor, Obs & Gynae, Altibri Medical college & Hospital, isra University karachi
Shagufta Perveen
Assistant professor, Obs & Gynae, Altibri Medical college & Hospital, isra University karachi campus
Nelofar Fahad
Consultant diabetologist and endocrinologist, Al-Habib Medical center, karachi
Sonia Khan
Associate professor, Department of Pharmacology, Al tibri Medical college, isra University karachi campus
Misha Fatima
Second Year, Pre –Medical student, karachi, Pakistan